Pranav Gupta

4.8k total citations · 3 hit papers
77 papers, 3.9k citations indexed

About

Pranav Gupta is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Pranav Gupta has authored 77 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 30 papers in Molecular Biology and 16 papers in Surgery. Recurrent topics in Pranav Gupta's work include Drug Transport and Resistance Mechanisms (36 papers), Cancer therapeutics and mechanisms (16 papers) and HIV/AIDS drug development and treatment (13 papers). Pranav Gupta is often cited by papers focused on Drug Transport and Resistance Mechanisms (36 papers), Cancer therapeutics and mechanisms (16 papers) and HIV/AIDS drug development and treatment (13 papers). Pranav Gupta collaborates with scholars based in United States, China and India. Pranav Gupta's co-authors include Zhe‐Sheng Chen, Charles R. Ashby, Rishil J. Kathawala, Leli Zeng, Hui Chao, Liang‐Nian Ji, Yanglu Chen, Enju Wang, Dong‐Hua Yang and Jing‐Quan Wang and has published in prestigious journals such as Chemical Society Reviews, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Pranav Gupta

75 papers receiving 3.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

2017 876 citations Leli Zeng, Pranav Gupta et al. Chemical Society Reviews profile →
The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade

2014 608 citations Rishil J. Kathawala, Pranav Gupta et al. profile →
Modulating ROS to overcome multidrug resistance in cancer

2018 545 citations Qingbin Cui, Jing‐Quan Wang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pranav Gupta United States	29	2.1k	1.8k	702	413	369	77	3.9k
Dong‐Hua Yang United States	41	2.1k 1.0×	3.2k 1.8×	421 0.6×	459 1.1×	813 2.2×	184	5.8k
Patric J. Jansson Australia	42	2.4k 1.1×	2.6k 1.4×	981 1.4×	192 0.5×	466 1.3×	85	5.5k
Zhi Shi China	42	1.6k 0.7×	2.4k 1.3×	305 0.4×	214 0.5×	635 1.7×	122	4.3k
Chanakya Nath Kundu India	38	990 0.5×	2.1k 1.2×	767 1.1×	385 0.9×	436 1.2×	124	4.1k
Catherine Booth-Genthe United States	10	1.8k 0.8×	1.7k 1.0×	227 0.3×	404 1.0×	366 1.0×	13	3.3k
Paul M. Loadman United Kingdom	37	1.1k 0.5×	2.1k 1.2×	585 0.8×	410 1.0×	865 2.3×	152	4.0k
Sushil K. Kashaw India	29	1.2k 0.5×	1.6k 0.9×	1.6k 2.3×	463 1.1×	238 0.6×	131	4.7k
Wenfang Xu China	37	1.6k 0.7×	3.0k 1.7×	1.7k 2.4×	185 0.4×	600 1.6×	266	5.2k
Roger M. Phillips United Kingdom	38	1.4k 0.7×	2.1k 1.2×	1.7k 2.4×	454 1.1×	737 2.0×	162	4.9k
Bin Yu China	46	999 0.5×	3.7k 2.1×	2.8k 4.0×	258 0.6×	517 1.4×	220	7.2k

Countries citing papers authored by Pranav Gupta

Since Specialization

Citations

This map shows the geographic impact of Pranav Gupta's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pranav Gupta with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pranav Gupta more than expected).

Fields of papers citing papers by Pranav Gupta

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pranav Gupta. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pranav Gupta. The network helps show where Pranav Gupta may publish in the future.

Co-authorship network of co-authors of Pranav Gupta

This figure shows the co-authorship network connecting the top 25 collaborators of Pranav Gupta. A scholar is included among the top collaborators of Pranav Gupta based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pranav Gupta. Pranav Gupta is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gupta, Mohit, Brijesh Kumar, Varun Sharma, et al.. (2025). Clinical features, imaging characteristics, and genetic profile of hypertrophic cardiomyopathy patients in India. Indian Heart Journal. 77(6). 416–423.

Gupta, Pranav, et al.. (2024). Chemical Derivatization Leads to the Discovery Of Novel Analogs of Azotochelin, a Natural Siderophore, as Promising Anticancer Agents. ChemMedChem. 19(13). e202300715–e202300715. 1 indexed citations

Gupta, Pranav, Zi‐Ning Lei, Sandra E. Reznik, et al.. (2020). BMS-599626, a Highly Selective Pan-HER Kinase Inhibitor, Antagonizes ABCG2-Mediated Drug Resistance. Cancers. 12(9). 2502–2502. 13 indexed citations

Zhang, Guan-Nan, Pranav Gupta, Ming Wang, et al.. (2020). Lipid–Saporin Nanoparticles for the Intracellular Delivery of Cytotoxic Protein to Overcome ABC Transporter-Mediated Multidrug Resistance In Vitro and In Vivo. Cancers. 12(2). 498–498. 11 indexed citations

Kathawala, Rishil J., Claudia M. Espitia, Pranav Gupta, et al.. (2020). ABCG2 Overexpression Contributes to Pevonedistat Resistance. Cancers. 12(2). 429–429. 13 indexed citations

Cai, Chao‐Yun, Wei Zhang, Jing‐Quan Wang, et al.. (2020). Biological evaluation of non-basic chalcone CYB-2 as a dual ABCG2/ABCB1 inhibitor. Biochemical Pharmacology. 175. 113848–113848. 28 indexed citations

Gupta, Pranav, et al.. (2019). Ciprofloxacin Enhances the Chemosensitivity of Cancer Cells to ABCB1 Substrates. International Journal of Molecular Sciences. 20(2). 268–268. 35 indexed citations

Liao, Dan, Wei Zhang, Pranav Gupta, et al.. (2019). Tetrandrine Interaction with ABCB1 Reverses Multidrug Resistance in Cancer Cells Through Competition with Anti-Cancer Drugs Followed by Downregulation of ABCB1 Expression. Molecules. 24(23). 4383–4383. 55 indexed citations

Narayanan, Silpa, et al.. (2019). Anti-cancer effect of Indanone-based thiazolyl hydrazone derivative on colon cancer cell lines. The International Journal of Biochemistry & Cell Biology. 110. 21–28. 40 indexed citations

10.

Cai, Chao‐Yun, Zi‐Ning Lei, Cai‐Ping Tan, et al.. (2019). Benzoyl indoles with metabolic stability as reversal agents for ABCG2-mediated multidrug resistance. European Journal of Medicinal Chemistry. 179. 849–862. 33 indexed citations

11.

Cui, Qingbin, Chao‐Yun Cai, Jing‐Quan Wang, et al.. (2019). Chk1 Inhibitor MK-8776 Restores the Sensitivity of Chemotherapeutics in P-glycoprotein Overexpressing Cancer Cells. International Journal of Molecular Sciences. 20(17). 4095–4095. 26 indexed citations

12.

Zhang, Guan-Nan, Yunkai Zhang, Yi‐Jun Wang, et al.. (2018). Epidermal growth factor receptor (EGFR) inhibitor PD153035 reverses ABCG2-mediated multidrug resistance in non-small cell lung cancer: In vitro and in vivo. Cancer Letters. 424. 19–29. 48 indexed citations

13.

Ji, Ning, Yuqi Yang, Chao‐Yun Cai, et al.. (2018). Selonsertib (GS-4997), an ASK1 inhibitor, antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells. Cancer Letters. 440-441. 82–93. 91 indexed citations

14.

Fan, Yingfang, Wei Zhang, Leli Zeng, et al.. (2018). Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters. Cancer Letters. 421. 186–198. 96 indexed citations

15.

Gupta, Pranav, Zi‐Ning Lei, Dan Liao, et al.. (2018). Immuno-oncology agent IPI-549 is a modulator of P-glycoprotein (P-gp, MDR1, ABCB1)-mediated multidrug resistance (MDR) in cancer: In vitro and in vivo. Cancer Letters. 442. 91–103. 49 indexed citations

16.

Ji, Ning, Yuqi Yang, Zi‐Ning Lei, et al.. (2018). Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Biochemical Pharmacology. 158. 274–285. 47 indexed citations

17.

Zeng, Leli, Pranav Gupta, Yanglu Chen, et al.. (2017). The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. Chemical Society Reviews. 46(19). 5771–5804. 876 indexed citations breakdown →

18.

Gupta, Pranav, Silpa Narayanan, Yi‐Jun Wang, et al.. (2017). GSK1904529A, a Potent IGF‐IR Inhibitor, Reverses MRP1‐Mediated Multidrug Resistance. Journal of Cellular Biochemistry. 118(10). 3260–3267. 19 indexed citations

19.

Zhang, Xiaoyu, Yunkai Zhang, Yi‐Jun Wang, et al.. (2016). Osimertinib (AZD9291), a Mutant-Selective EGFR Inhibitor, Reverses ABCB1-Mediated Drug Resistance in Cancer Cells. Molecules. 21(9). 1236–1236. 39 indexed citations

20.

Anreddy, Nagaraju, Pranav Gupta, Rishil J. Kathawala, et al.. (2014). Tyrosine Kinase Inhibitors as Reversal Agents for ABC Transporter Mediated Drug Resistance. Molecules. 19(9). 13848–13877. 90 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact